Search results for "Follow-up studies"

showing 10 items of 2210 documents

Rationale and methods for a randomized controlled trial of a movement-to-music video program for decreasing sedentary time among mother-child pairs

2015

Measured objectively, under a quarter of adults and fewer than half of preschool children meet the criteria set in the aerobic physical activity recommendations of the Centers for Disease Control and Prevention. Moreover, adults reportedly are sedentary (seated or lying down) for most of their waking hours. Importantly, greater amounts of sedentary time on parents’ part are associated with an increased risk of more sedentary time among their children. A randomized controlled trial targeting mother-child pairs has been designed, to examine whether a movement-to-music video program may be effective in reducing sedentary time and increasing physical activity in the home environment. Mother-chi…

AdultMaleProgram evaluationmedicine.medical_specialtyMothersmotivational musicphysical activityHealth Promotionvideolaw.inventionStudy ProtocolScreen timeMovement-to-musicRandomized controlled trialQuality of lifelawSurveys and QuestionnairesIntervention (counseling)sedentary behaviormedicineHumansTerveystiede - Health care scienceChildExerciseFinlandSedentary lifestyleMotivationPhysical activityMotivational musicbusiness.industryPublic Health Environmental and Occupational HealthVideotape RecordingVideoMother-Child RelationsUnited States3. Good healthSedentary behaviorChild PreschoolCohortQuality of LifePhysical therapyFemaleBiostatisticsbusinessMusicmovement-to-musicFollow-Up StudiesProgram Evaluation
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct

The influence of medication on the course of major depression: a 3-year-follow-up with polydiagnostic measures.

1988

AdultMalePsychiatric Status Rating Scalesmedicine.medical_specialtyDepressive Disorderbusiness.industryGeneral MedicineMiddle AgedAntidepressive AgentsPsychiatry and Mental healthMedicineHumansPharmacology (medical)FemalebusinessPsychiatryDepression (differential diagnoses)Follow-Up StudiesPharmacopsychiatry
researchProduct

Predictors of neurocognitive impairment at 3years after a first episode non-affective psychosis

2013

Abstract Background Neurocognitive impairment is a core component of schizophrenia. However, patients show great variability in the level and course of deficits. The goal of the present longitudinal study was to identify predictors of neurocognitive impairment in first episode psychosis patients. Methods N eurocognitive performance was analyzed in a cohort of 146 patients 3 years after a first episode non-affective psychosis. Subgroups, impaired vs. unimpaired, were compared on baseline clinical, neuropsychological, premorbid and sociodemographic characteristics. Results Fifty-nine percent of participants presented general neurocognitive impairment and regression analyses demonstrated that …

AdultMalePsychosisAdolescentTrail Making TestPoison controlNeuropsychological TestsYoung AdultMemoryPredictive Value of TestsmedicineHumansLongitudinal StudiesBiological PsychiatryIntelligence TestsPsychiatric Status Rating ScalesPharmacologyFirst episodeTrail Making TestWechsler ScalesNeuropsychologyMiddle AgedPrognosismedicine.diseaseDiagnostic and Statistical Manual of Mental DisordersPsychotic DisordersSocioeconomic FactorsMotor SkillsSchizophreniaSchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyVerbal memoryCognition DisordersPsychologyNeurocognitiveFollow-Up StudiesClinical psychologyProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Early developmental milestones in adult schizophrenia and other psychoses. A 31-year follow-up of the Northern Finland 1966 Birth Cohort

2001

Abstract Delayed childhood development may precede adult psychoses. We tested this hypothesis in a large, general population birth cohort (n=12 058) followed to age 31 years. The ages at which individuals learned to stand, walk, speak, and became potty-trained (bowel control) and dry (bladder control), were recorded at a 1-year examination. Psychiatric outcome was ascertained through linkage to a national hospital discharge register. Cumulative incidence of DSM-III-R schizophrenia, other psychoses and non-psychotic disorders were stratified according to the timing of milestones and compared within the cohort using internal standardization. 100 cases of DSM-III-R schizophrenia, 55 other psyc…

AdultMalePsychosismedicine.medical_specialtyAdolescentDevelopmental DisabilitiesPopulationCohort StudiesReference ValuesmedicineHumansCumulative incidenceChildeducationPsychiatryFinlandBiological PsychiatryNeurologic ExaminationPsychomotor learningeducation.field_of_studyIncidence (epidemiology)Infantmedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaChild PreschoolCohortDevelopmental MilestoneSchizophreniaFemaleSchizophrenic PsychologyPsychomotor DisordersPsychologyFollow-Up StudiesSchizophrenia Research
researchProduct

Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer

2012

Abstract Background Adherence to erlotinib could be a determinant for clinical outcome and treatment toxicity in patients with advanced non–small-cell lung cancer (A-NSCLC). Patients and Methods In an observational study, the Basel Assessment of Adherence Scale (BAAS), a visual analogue scale (VAS), pill counting, and missed appointment rate were used to evaluate adherence in a first cohort of patients who was prescribed erlotinib without a specifically designed management strategy and in a second cohort of patients followed by an oral treatment monitoring program. Results Adherence > 95% by BAAS at 2 months of treatment in the first and second cohorts was 72% and 84%, respectively ( P = .0…

AdultMalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsVisual analogue scaleAdenocarcinomaMedication AdherenceErlotinib HydrochlorideCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansErlotinib HydrochlorideProtein Kinase InhibitorsSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overSalvage Therapybusiness.industryHealth Plan ImplementationRetrospective cohort studyAdenocarcinoma Bronchiolo-AlveolarMiddle AgedPrognosisSmall Cell Lung CarcinomaMonitoring programConfidence intervalSurgerySurvival RateOncologyCohortQuinazolinesCarcinoma Large CellPatient ComplianceFemaleErlotinibDrug MonitoringbusinessFollow-Up Studiesmedicine.drugClinical Lung Cancer
researchProduct

Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis

1996

There is mounting evidence that activated interleukin 2 (IL-2)-releasing lymphocytes play a central role in the immunopathogenesis of sarcoidosis by directing inflammatory reactions and granuloma formation. In the context that a significant proportion of these cells accumulates in the lung and releases mediators, we hypothesized that different immunologically defined stages of sarcoidosis can be identified. A cohort of 89 sarcoidosis patients was allocated to four groups according to the following criteria: stage A, a low number of bronchoalveolar lavage (BAL) lymphocytes (20%) without IL-2 release (1 unit/ml in BAL cell culture supernatant); stage B, BAL lymphocytes20%, with IL-2 release (…

AdultMalePulmonary and Respiratory MedicineInterleukin 2T-LymphocytesContext (language use)InflammationStatistics NonparametricPulmonary function testingSarcoidosis PulmonarymedicineHumansCells CulturedChi-Square DistributionLungmedicine.diagnostic_testbusiness.industryrespiratory systemPrognosismedicine.diseaserespiratory tract diseasesBronchoalveolar lavagemedicine.anatomical_structureImmunologyInterleukin-2FemaleSarcoidosismedicine.symptombusinessBronchoalveolar Lavage FluidProgressive diseaseFollow-Up Studiesmedicine.drugLung
researchProduct

Airway neutrophilia in COPD is not associated with increased neutrophil survival

2006

Neutrophilic airway inflammation is a prominent feature of chronic obstructive pulmonary disease (COPD) and correlates with disease severity. The mechanisms that determine the extent of neutrophilia could involve increased influx or prolonged survival of neutrophils. The aim of the study was to assess whether neutrophil pro-survival mechanisms are increased in the airways of subjects with COPD owing to the presence of anti-apoptotic factors in the bronchial lining fluid. Induced sputum samples were collected from 20 subjects with stable COPD, 14 healthy smokers and 14 healthy controls. Quantification of apoptotic neutrophils was based on typical morphological cell changes. Anti-apoptotic, p…

AdultMalePulmonary and Respiratory MedicineNeutrophilsNeutrophileRespiratory SystemApoptosisInflammationGranulocyteNeutrophil ActivationPulmonary Disease Chronic ObstructiveForced Expiratory VolumeHumansMedicineAnnexin A5Cells CulturedAgedCOPDbusiness.industrySmokingRespiratory diseaseSputumMiddle AgedFlow Cytometrymedicine.diseaseNeutrophiliarespiratory tract diseasesmedicine.anatomical_structureCase-Control StudiesImmunologySputumFemalemedicine.symptomAirwaybusinessFollow-Up StudiesEuropean Respiratory Journal
researchProduct

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

2013

Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists. To further explore the dose–response curve in asthma, we investigated the efficacy and safety of three different doses of tiotropium Respimat® as add-on to ICS in symptomatic patients with moderate persistent asthma. In this randomised, double-blind, placebo-controlled, four-way crossover study, patients were randomised to tiotro…

AdultMalePulmonary and Respiratory MedicineRespimatmedicine.drug_classScopolamine DerivativesPlaceboFEV1/FVC ratioDouble-Blind MethodCholinergic antagonistsBronchodilatorAdministration InhalationmedicineHumansTiotropium BromideAsthmaCross-Over StudiesDose-Response Relationship Drugbusiness.industryResearchTiotropiumTiotropium bromideMiddle AgedBronchodilator agentsmedicine.diseaseDose-ranging studyCrossover studyAsthmaRespimatrespiratory tract diseasesClinical trialAnesthesiaFemalebusinessmedicine.drugFollow-Up StudiesRespiratory Research
researchProduct

Cardiac surgery outcomes in patients with coronavirus disease 2019 (COVID-19): A case-series report

2020

Abstract Objective The impact of coronavirus disease 2019 (COVID-19) on the postoperative course of patients after cardiac surgery is unknown. We experienced a major severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in our cardiac surgery unit, with several patients who tested positive early after surgery. Here we describe the characteristics, postoperative course, and laboratory findings of these patients, along with the fate of the health care workers. We also discuss how we reorganize and reallocate hospital resources to resume the surgical activity without further positive patients. Methods After diagnosis of the first symptomatic patient, surgery was suspended. Naso…

AdultMalePulmonary and Respiratory MedicineSIRS systemic inflammatory response syndromemedicine.medical_specialtyInfectious Disease Transmission Patient-to-ProfessionalCoronavirus disease 2019 (COVID-19)Sars-CoV-2medicine.medical_treatmentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)cardiac surgery COVID-19 new coronavirus SARS-CoV-2CRP C-reaction protein030204 cardiovascular system & hematologyHealth Services AccessibilityArticleDisease OutbreaksTertiary Care Centers03 medical and health sciences0302 clinical medicinePostoperative ComplicationsValve replacementInterquartile rangeInternal medicineHealth caremedicineHumansIn patientCardiac Surgical ProceduresAgedAged 80 and overInfection ControlHealth Care RationingTAVR transcatheter aortic valve replacementbusiness.industrynew coronavirusExtracorporeal circulationCOVID-19Middle AgedCardiac surgery030228 respiratory systemItalyRT-PCR t real-time reverse transcription polymerase chain reactionFemaleSurgeryCOVID-19 / Sars-CoV-2 novel coronavirus 2businessCardiology and Cardiovascular Medicinecardiac surgeryFollow-Up Studies
researchProduct